AbbVie 2026 Pipeline Highlights and Key Regulatory Decisions Summary

AbbVie: Key pipeline development highlights and 2026 regulatory submissions (from 2026 Q1 earnings materials)

Based on AbbVie’s 2026 Q1 earnings discussion, management emphasized several pipeline-development items that directly map to “upcoming” regulatory activity and submission timing across immunology, neuroscience, oncology, obesity, and other areas. Below are the clearest 2026-related highlights mentioned in the excerpts.

---

1) Immunology: new submissions and expansion of Crohn’s/Skyrizi program (2026)

Rinvoq for Alopecia Areata (U.S. regulatory submission completed)

• AbbVie highlighted U.S. regulatory submissions of Rinvoq for alopecia areata as a recent milestone, positioning it as a potential new dermatology growth source. ¹

Why it matters for 2026: this is explicitly framed as a U.S. submission already made (“recent highlights include…”), so the key 2026 regulatory pathway is progress toward review/decision rather than initiating the submission. ¹

Skyrizi subcutaneous induction in Crohn’s (U.S. decision expected later in 2026)

• AbbVie also cited Skyrizi subcu induction in Crohn’s with an approval decision expected later this year (2026). ¹

Ongoing Crohn’s platform development (dose/formulation optimization + potential acceleration)

Management discussed a Crohn’s “platform” combining Skyrizi with other assets (including alpha 4 beta 7 and TL1A), including:

• A Phase IIb plan to study a higher dose of 382 in combination with Skyrizi, aiming to potentially improve efficacy; AbbVie noted that interim data showed a non-flat exposure-response slope (higher exposure correlated with better outcomes). ²
• Monthly dosing/co-formulation work is ongoing, and AbbVie indicated they are speaking with regulators with a stated potential to further accelerate, not waiting for completion of Phase IIb if signals appear. ²
• AbbVie stated the goal to start a Phase III in ~2 years (or sooner), contingent on acceleration opportunities. ²
• The platform study also includes TL1A and will evaluate ulcerative colitis along with Crohn’s. ²

Why it matters for 2026 regulatory submissions: while the excerpts do not say “submit in 2026” for Crohn’s platform Phase II/III, they do explicitly frame potential regulatory acceleration as being discussed now, which could affect submission timing later. ²

---

2) Obesity: ABBV-295 clinical progress feeding future submissions (with Phase timing in 2026)

Early top-line results (supporting continued development)

• AbbVie reported early top-line results from a multiple ascending dose study of ABBV-295, showing clinically meaningful weight loss of nearly 10% after 12 weeks, with mostly mild and transient GI adverse events and no cases of severe nausea, vomiting or diarrhea. ³

2026 development schedule (incremental steps likely to lead toward later regulatory activity)

• AbbVie stated interim data from the Phase I study in obese patients are anticipated later this year (2026). ³
• AbbVie said the Phase II program is now expected to begin in the third quarter. ³

Why it matters for “upcoming regulatory submissions in 2026”: the excerpt does not explicitly state an obesity NDA/BLA submission in 2026. Instead, AbbVie’s communications suggest 2026 is about progressing to later-stage evidence (Phase II beginning in Q3; Phase I interim later in the year), which typically precedes regulatory filings in later years. ³

---

3) Oncology: multiple programs with 2026 submission timing or acceleration signals

Regulatory submission expected by end of 2026 (timing pulled forward)

• AbbVie said it is now expecting the regulatory submission for an oncology asset (the specific name is indiscernible in the excerpt) by the end of this year, and that this timing is earlier than previously expected. ¹

Why it matters: this is the most direct “upcoming regulatory submission in 2026” statement in oncology. ¹

Hematologic oncology: Phase III tracking and possible later-2026 submissions (contingent on interim readout)

• AbbVie discussed a Phase III trial evaluating a monotherapy in third-line plus multiple myeloma tracking ahead of schedule. ⁴
• AbbVie anticipates a response rate readout in the third quarter, and “potential to also see an interim analysis on progression-free survival.” ⁴
• AbbVie stated that if the interim analysis is positive, regulatory submissions would occur later this year (2026). ⁴

Solid tumor program: Temab-A strategy update and Phase III readiness for readouts

The excerpt contains key development/acceleration context relevant to future regulatory filings:

• In colorectal cancer, AbbVie updated strategy for Temab-A: pivotal program now focuses on Temab-A + bevacizumab in an all-comers population (instead of monotherapy in cMET-selected patients). ⁵
• AbbVie gave efficacy figures for Temab-A + bevacizumab: objective response rate 30% and confirmed disease control rate 97% vs 0% and 70% for the comparator (values are stated explicitly; comparator description is partially indiscernible). ⁵
• AbbVie expected initial data readout in the second half of next year (i.e., 2027). ⁵
• In lung cancer, AbbVie said Temab-A received its first breakthrough therapy designation as monotherapy in a second-line plus setting; AbbVie is planning a Phase III trial. ⁵
• In small cell lung cancer, AbbVie noted a Phase III trial for monotherapy (ABBV-706) recently began in relapsed/refractory patients; two Phase II studies evaluating ABBV-706 triplet combinations were planned to initiate “this year” (2026). ⁵

Why it matters for 2026 regulatory submissions: the colorectal readout expectation is in 2H 2027, which suggests 2026 is more about trials/strategic ramp-up than imminent submission for Temab-A in that setting. ⁵ The clear “regulatory submissions in 2026” language for oncology in these excerpts is therefore primarily the (indiscernible) oncology submission by end of 2026 and the multiple myeloma contingent submissions later this year. ¹⁴

---

4) Neuroscience: 2026 approval decision and other trial readouts feeding regulatory timing

Tavapadon approval decision expected in Q3 2026

• AbbVie stated it remains on track for an approval decision for tavapadon in the third quarter. ⁶

Why it matters: this is directly tied to a regulatory milestone occurring in 2026 (approval decision timing). ⁶

ABBV-932 (bipolar depression) Phase II top-line: signal in subgroup

• AbbVie stated top-line analysis was recently completed on a Phase II trial evaluating ABBV-932 in bipolar depression.
• The overall difference versus placebo was not statistically significant, but AbbVie reported an efficacy signal in a prespecified subgroup of bipolar I patients. ⁷
• AbbVie also said it is evaluating next steps to continue 932 development in bipolar 1 patients. ⁷

Why it matters for 2026 submissions: the excerpt does not specify an NDA/BLA filing plan or submission timing for 932 in 2026, but it suggests evidence generation and potential refinement in 2026. ⁷

Psychedelic acid brain (Phase II/Phase III planning in 2026)

AbbVie described:

• Additional data from an ongoing Phase II study in major depressive disorder available “this year.” ⁶
• Several studies planned to begin in 2026, including a Phase III trial for single-course acute treatment in MDD and Phase IIb repeat dosing for chronic use, plus a proof-of-concept Phase II and post-traumatic stress disorder. ⁶

Why it matters: again, these are trial initiations and evidence-building steps in 2026, not explicit submissions in 2026. ⁶

---

5) Other notable development/regulatory pathway item: Aesthetics CRL (resubmission path)

While not “pipeline submissions in 2026” for a new program, AbbVie addressed regulatory interaction in aesthetics:

• The FDA issued a complete response letter (CRL) for an aesthetics application related to manufacturing questions; AbbVie stated the CRL identified no issues related to safety, efficacy, or labeling and no additional clinical trials were requested. ⁴
• AbbVie said it will work closely with the FDA to address feedback and determine next steps for resubmission. ⁴

Why it matters for 2026 regulatory submissions: the excerpt does not specify the exact resubmission date, but it clearly identifies the regulatory path as “resubmission” after manufacturing-related feedback. ⁴

---

Consolidated view: what the excerpts imply for 2026 regulatory activity

Clear “upcoming/expected” 2026 submission/decision items explicitly stated

• Rinvoq (alopecia areata): U.S. regulatory submission completed (“recent highlights”). ¹
• Skyrizi subcu induction in Crohn’s: approval decision expected later in 2026. ¹
• Oncology: regulatory submission expected by end of 2026 (specific drug name indiscernible). ¹
• Multiple myeloma Phase III: if interim PFS analysis is positive, regulatory submissions would occur later in 2026. ⁴
• Tavapadon: approval decision expected in Q3 2026. ⁶
• Aesthetics CRL: resubmission path being developed (timing not specified). ⁴

2026 development that appears designed to feed future regulatory filings

• ABBV-295 obesity: Phase I interim data later in 2026; Phase II begins in Q3 2026. ³
• Crohn’s platform (Skyrizi + 382 + TL1A): Phase IIb optimization (higher 382 dose), monthly dosing/co-formulation work ongoing, and potential acceleration discussions with regulators. ²
• Solid tumor/Temab-A and ABBV-706: trial planning and strategy updates, with at least one key readout expected in 2H 2027. ⁵

---

Bottom line

In the provided 2026 Q1 excerpts, AbbVie’s “key highlights” for pipeline development tied to 2026 regulatory submissions/decisions cluster around: (i) immunology filings and a Crohn’s approval decision (Rinvoq alopecia areata submission; Skyrizi Crohn’s decision), (ii) multiple oncology regulatory submissions with explicit end-of-year/timing conditions (including a submission by end of 2026 and potential later-2026 myeloma submissions), and (iii) neuroscience approval timing (tavapadon decision in Q3 2026). ¹⁴⁶ In parallel, obesity (ABBV-295) is progressing through Phase I interim/Phase II start steps in 2026, which typically sets up later regulatory filings rather than immediate submissions that year. ³